Merck Imposes Temporary Surcharges on All Shipments to China Amid Tariff Pressures; Publicly Procured Trivalent Influenza Vaccine Hits Record-Low Bid Price
OYMotion
Provider of Rehabilitation Medical Technology Solutions
CHIATAI TIANQING
High-quality pharmaceuticals research, production, and sales provider
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
© Amino Observation - Innovative Drug Team Original Production
Author | Huang Kai
The impact of tariffs is becoming apparent.
On May 11, Merck Germany announced that due to the impact of tariffs, a temporary surcharge would be applied to all product orders shipped to China starting from May 12.
Vaccine prices continue to drop.
On May 13, Shenzhen Public Resources Trading Center announced the winning bid (transaction) results for the free influenza vaccine vaccination program for primary and secondary school students in Shenzhen. The announcement showed that Fosun Yalifeng won the bid for the trivalent influenza vaccine (0.5ml), with a winning price of 8 yuan per dose, totaling 1.6 million doses.
The price hit a new low for publicly funded trivalent influenza vaccine bids. Meanwhile, the other two candidate winning suppliers, Changchun Institute of Biological Products and Beijing Sinovac, quoted 8.35 yuan/dose and 8.8 yuan/dose respectively, both falling below 9 yuan.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) The winning bid price for government-funded trivalent influenza vaccines hits a new low.
On May 13, Shenzhen Public Resources Trading Center announced the winning bid (transaction) results for the free influenza vaccine vaccination program for primary and secondary school students in Shenzhen. The announcement showed that Fosun Yalifeng won the bid for the trivalent influenza vaccine (0.5ml) at a price of 8 yuan per dose, with a total quantity of 1.6 million doses. This price set a new low for publicly funded trivalent influenza vaccines. Additionally, the other two candidate suppliers, Changchun Institute of Biological Products and Beijing Sinovac, quoted 8.35 yuan per dose and 8.8 yuan per dose respectively, both falling below 9 yuan.
/ 02 /
Capital Information
1) OYMotion Completes Nearly RMB100 Million in B++ Round Financing
On May 13, OYMotion Technology Co., Ltd., a company in the brain-computer interface and robotics fields, announced the completion of a nearly 100-million-yuan B++ round of financing.
/ 03 /
Pharmaceutical News
1) Pfizer's PD-L1 ADC Initiates Clinical Trials in China for the First Time
On May 13, the Drug Clinical Trial Registration and Information Disclosure Platform showed that Pfizer launched a Phase I clinical trial of PF-08046054 for patients with solid tumors in China. PF-08046054 (SGN-PDL1V) is a PD-L1-targeted ADC acquired by Pfizer through its acquisition of Seagen.
2) First-line treatment for advanced liver cancer: CHIATAI TIANQING announces Phase 3 clinical data of combination therapy
On May 13, CHIATAI TIANQING announced that the results of the pivotal Phase 3 clinical trial (APOLLO study) for Anlotinib Capsules combined with Penpulimab Injection as first-line treatment for advanced hepatocellular carcinoma (HCC) were published in The Lancet Oncology (IF: 41.6), an oncology journal under The Lancet.
3) Yilian Bio's VEGF ADC Receives Clinical Approval in the U.S.
On May 13, Yilian Biotech announced that its VEGF-targeted antibody-drug conjugate (ADC) YL242 had received the FDA's clinical trial approval by default.
4) Abbisko Therapeutics will announce the latest data on the combination of irpagratinib and atezolizumab for the treatment of advanced hepatocellular carcinoma.
On May 13, Abbisko Therapeutics announced that it will present the latest clinical trial data of its self-developed highly selective small molecule FGFR4 inhibitor, Epatogotinib, in combination with Atezolizumab for the treatment of advanced hepatocellular carcinoma patients, at the 2025 European Society for Medical Oncology Gastrointestinal Cancers Congress (ESMO GI).
5) Shijian Biotech TROP2 ADC Breast Cancer Brain Metastasis Data Released
On May 13, Shijian Biotech announced that the clinical research results of its TROP2 ADC drug ESG401 for the treatment of brain metastases in patients with advanced HER2-negative breast cancer have been officially published online in ESMO Open, an internationally renowned medical journal hosted by the European Society for Medical Oncology (ESMO).
/ 04 /
Overseas Pharmaceutical News
1) Genentech, a subsidiary of Roche, plans to invest over $700 million in building a pharmaceutical factory in the U.S.
On May 13, Genentech, a member of the Roche Group, announced plans to invest over $700 million in building a state-of-the-art pharmaceutical manufacturing facility in Holly Springs, North Carolina, USA. The statement noted that the new plant will eventually support Roche and Genentech's next-generation obesity drug portfolio, and this initial investment may expand in the future based on business needs and the U.S. policy environment.
2) Merck Germany will increase prices for all products shipped to China
On May 11, Merck Germany issued a notice stating that, due to the impact of tariffs, a temporary surcharge would be applied to all product orders shipped to China starting from May 12.
PS: Welcome to scan the QR code below to add the WeChat ID of Amino for communication.